Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - ranitidinas - plėvele dengtos tabletės - 150 mg - ranitidine

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

chemifarma s.p.a. (italija) - geriamasis tirpalas - zantac zantac tylosin (as tartrate) – 200.0 mg; excipients up to 1.0 ml - broileriams ir kalakutams, sergantiems lėtinėmis užkrečiamomis kvėpavimo organų ligomis, gydyti.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresantai - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine hidrochloridas - depresijos sutrikimas - kiti antidepresantai - spravato, kartu su ssri ar snri, yra nurodyta suaugusiųjų gydymas-atsparus didžiosios depresijos sutrikimas, kuris nebuvo atsakyta į ne mažiau kaip dviejų skirtingų gydymo antidepresantais dabartinio vidutinio sunkumo ir sunkios depresijos epizodas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

merck europe b.v. - cladribine - išsėtinė sklerozė - imunosupresantai - suaugusių pacientų su labai aktyvaus recidyvuojančia išsėtine skleroze (is) nustatytus klinikinių ar vizualizavimo įranga.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astellas pharma europe bv - takrolimuzas - dantų atmetimas - imunosupresantai - profilaktiškai transplantacijos atmetimo suaugusiųjų inkstų arba kepenų allograft gavėjams. gydyti atmetimo, atsparūs gydymo imuninę sistemą slopinančiais vaistiniais preparatais suaugusių pacientų alotransplantato atmetimo reakciją.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresantai - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriazinis arthritiscosentyx, atskirai arba kartu su metotreksatas (mtx), yra nurodyta, kad gydymo aktyviai psoriaziniu artritu suaugusių pacientų, kai atsakas į ankstesnius ligos keičiant stabdžių reumatinės narkotikų (dmard) gydymas buvo netinkamas. centrinis spondyloarthritis (axspa)ankilozuojantis spondilitas (as, radiografijos centrinis spondyloarthritis)cosentyx fluorouracilu ir folino aktyvių ankilozuojantis spondilitas yra suaugusiųjų, kurie reagavo netinkamai tradicinių terapijos. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresantai - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - imunosupresantai - psoriazinis arthritisotezla, atskirai arba kartu su liga, keičiančių priešreumatiniai vaistai (dmards), yra nurodyta, kad gydymo aktyviai psoriazinis artritas (psa) suaugusių pacientų, kuriems buvo nepakankama arba kuriems buvo netoleruoja prieš dmard terapija. psoriasisotezla fluorouracilu gydyti vidutinio sunkumo arba sunkus lėtinis plokštelinės psoriazės suaugusiųjų pacientai, kurie nereagavo į arba kurie yra kontraindikacijos, ar netoleruoja kitų sisteminės terapijos įskaitant ciklosporino, metotreksato arba psoralen ir ultravioletinės-šviesos (puva).